To verify the possibility to collect HER2-low CTCs from metastatic breast cancer patient samples bearing at least 5 CTCs applying the cut-offs, four samples (Pt1, Pt2, Pt3, and Pt4), derived from four different patients, underwent the entire pipeline (Table 3). This evidence concerns the gene ERBB2 and breast carcinoma.